No Single Test Can Reliably Diagnose Respiratory Sarcopenia, Landmark Review Finds

For millions of older adults, the muscles that power every breath quietly weaken with age, a condition researchers call respiratory sarcopenia. It has been linked to pneumonia, hospitalization, and even death, yet doctors still have no reliable way to diagnose it. Now a sweeping systematic review and meta-analysis published in European Geriatric Medicine has quantified just how uncertain that diagnosis remains, finding that the three most commonly used breathing tests miss a troubling proportion of cases and that the evidence is not strong enough to crown any one of them as a clinical standard.

The research team, led by physiotherapy researchers at the Federal University of Pernambuco in Brazil, searched eight databases and the grey literature for studies testing how well respiratory muscle measures identify respiratory sarcopenia in people aged sixty and over. From 647 initial records, only seven studies made the final cut, together covering 2,466 participants with mean ages between 70.2 and 80.6 years. Four of the studies came from Japan, two from South Korea, and just one from Brazil, a geographic concentration the authors flag as a major limitation for generalizing the findings worldwide.

Because no universally accepted reference standard exists for respiratory sarcopenia itself, the primary studies anchored their diagnoses in established sarcopenia consensus frameworks, chiefly the Asian Working Group for Sarcopenia 2019 criteria and, in two studies, the European EWGSOP2 definition. Against that backdrop, the reviewers evaluated three distinct respiratory measures: maximal inspiratory pressure, or MIP, which gauges the strength of the muscles that draw air into the lungs; maximal expiratory pressure, or MEP, which reflects the force available for coughing and clearing the airways; and peak expiratory flow rate, or PEFR, a simple flow-based reading obtainable with inexpensive spirometry equipment.

The headline numbers are sobering. Across all tests combined, pooled sensitivity was just 0.614, meaning roughly four in ten people with the condition would be missed, while pooled specificity reached 0.726, implying a meaningful rate of false alarms. Even more striking was the heterogeneity: a bivariate I-squared of 0.929, indicating that more than nine-tenths of the variation between studies reflected genuine differences in methods, thresholds, and populations rather than chance. The authors caution that this combined figure should be read as a broad summary of heterogeneous approaches, not as the performance of any single interchangeable test.

When the tests were unpicked one by one, distinct diagnostic personalities emerged. MEP-based assessments, using the Sawaya model with sex-specific reference values, achieved the highest pooled sensitivity at 0.739 with comparatively low heterogeneity between studies. MIP-based approaches showed the highest specificity, 0.893, but a confidence interval stretching from 0.190 to 0.996 revealed severe imprecision, and sensitivity sat at a moderate 0.678. PEFR-based methods fared worst, with pooled sensitivity of just 0.418 and specificity of 0.606 alongside substantial between-study variability, despite the test’s obvious practical appeal of being quick, cheap, and easy to administer in community settings.

Underlying physiology may help explain why expiratory measures outperform inspiratory ones. Sarcopenia preferentially strips away fast-twitch muscle fibers, and the expiratory muscles, including the rectus abdominis, may be affected differently from the diaphragm, which has a different fiber composition. One of the included studies reported that expiratory, but not inspiratory, muscle strength was associated with sarcopenia, a finding the reviewers note fits this hypothesis, although they stress that the mechanisms remain to be formally investigated.

Exploratory subgroup analyses probed whether diagnostic performance differed by sex or by the sarcopenia criteria used. Sensitivity was higher in men, 0.742, than in women, 0.594, but meta-regression found no statistically detectable difference between the groups, and the same held true when AWGS- and EWGSOP2-based studies were compared. The authors are explicit that these analyses were underpowered given the small number of studies, so the absence of significant differences should not be mistaken for evidence that sex or choice of consensus criteria truly makes no difference.

Methodological quality added a further layer of caution. Using the QUADAS-2 tool, the reviewers judged all seven included studies to carry a moderate risk of bias, citing incomplete reporting of reference-test methods, insufficient blinding of assessors, and inconsistent documentation of who performed the tests and with what qualifications. The choice to extract a single sensitivity-specificity pair per study, based on the highest reported Youden index, may also have flattered the results by favoring study-specific optimal cutoffs. Formal publication bias and threshold-effect analyses were not feasible given the scarcity of studies for each construct.

The stakes extend well beyond classification. Respiratory sarcopenia has been associated with adverse outcomes including pneumonia and all-cause mortality, and interventional trials have shown that peripheral and respiratory muscle training can improve respiratory parameters in older adults, raising the tantalizing prospect that early detection could trigger interventions that delay or prevent decline. Emerging imaging techniques such as ultrasound and computed tomography can quantify respiratory muscle mass, and reduced diaphragm thickness has been linked to sarcopenia, but a lack of validated reference values, particularly in older populations, has kept these tools out of routine practice.

The review’s bottom line is a call to action rather than a verdict. Current evidence, the authors conclude, is insufficient to establish the superiority of any single test or to recommend a clinical reference standard for respiratory sarcopenia. What is needed, they argue, are prospective multicenter studies spanning diverse populations with standardized diagnostic criteria, and an international consensus on how the condition itself should be defined. Until then, clinicians weighing MIP, MEP, or PEFR results in older patients should interpret them as imperfect, complementary windows on respiratory muscle health rather than definitive answers, and researchers now have a clear quantitative map of exactly how far the field must travel.

Subject of Research: Diagnostic accuracy of respiratory muscle tests for identifying respiratory sarcopenia in older adults

Article Title: Diagnostic uncertainty in respiratory sarcopenia: accuracy of available tests and clinical implications: a systematic review and meta-analysis

Article References: Diagnostic uncertainty in respiratory sarcopenia: accuracy of available tests and clinical implications: a systematic review and meta-analysis. (n.d.). https://doi.org/10.1007/s41999-026-01619-3

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01619-3

Keywords: respiratory sarcopenia, sarcopenia, diagnostic accuracy, maximal inspiratory pressure, maximal expiratory pressure, peak expiratory flow rate, older adults, systematic review, meta-analysis, pneumonia, geriatric medicine, muscle weakness